Molecular and Anatomic Imaging of Neuroendocrine Tumors

Abstract

Positron emission tomography (PET) with somatostatin receptor (SSTR) ligands has taken the lead in the imaging of neuroendocrine tumors (NETs). In this article, we review the role of SSTR PET scan in the management of NETs, including the indications for the scan, pitfalls in interpretation, and imaging selection criteria for peptide receptor radionuclide therapy. We also discuss the complementary role of fluorodeoxyglucose PET particularly for patients with high-grade disease.

Keywords: Appropriate use; Imaging; Management; Neuroendocrine tumor; Peptide receptor radionuclide therapy; Positron emission tomography; Somatostatin receptor.